Search Result

Isoforms Recommended:	SIRT2

Results for "

SIRT2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (21) Atg8/LC3 (1) Autophagy (10) c-Myc (1) Caspase (1) CMV (1) Dihydroorotate Dehydrogenase (3) Discoidin Domain Receptor (1) Drug Intermediate (1) Endogenous Metabolite (6) Environmental Pollutants (1) Exosomes (2) Fluorescent Dye (1) Fungal (1) HBV (6) HDAC (3) Histone Acetyltransferase (2) Histone Demethylase (1) HSP (3) Isotope-Labeled Compounds (3) Ligands for Target Protein for PROTAC (1) MDM-2/p53 (4) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) mTOR (1) Organoid (2) Parasite (3) PEPCK (1) Phosphatase (3) Phospholipase (2) PROTACs (3) Reference Standards (13) Reverse Transcriptase (3) SARS-CoV (5) Sirtuin (92) Small Interfering RNA (siRNA) (3) Topoisomerase (3)
By Research Areas:	Cancer (69) Cardiovascular Disease (3) Endocrinology (1) Infection (10) Inflammation/Immunology (8) Metabolic Disease (9) Neurological Disease (21)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

101

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0150

Nicotinamide 85+ Cited Publications Niacinamide; Nicotinic acid amide	Environmental Pollutants Endogenous Metabolite Sirtuin HBV Organoid	Cancer
Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits *SIRT2* activity (IC₅₀: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD₊, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity ^[2] .

HY-B0879A

Suramin sodium salt 20+ Cited Publications Suramin hexasodium salt	Phosphatase Sirtuin Reverse Transcriptase Topoisomerase SARS-CoV Parasite Apoptosis	Infection Cardiovascular Disease Cancer
Suramin sodium salt (Suramin hexasodium salt) is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor . Suramin sodium salt is a potent inhibitor of sirtuins: SirT1 (IC₅₀=297 nM), SirT2 (IC₅₀=1.15 μM), and SirT5 (IC₅₀=22 μM) ^[2]. Suramin sodium salt is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC₅₀=5 μM) . Suramin sodium salt is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor . Suramin sodium salt efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent .

HY-10532

SRT 1720 55+ Cited Publications	Sirtuin Autophagy	Metabolic Disease
SRT 1720 is a selective activator of human *SIRT1* with an EC_1.5 of 0.16 μM, and shows less potent activities for SIRT2 and SIRT3 with EC_1.5s of 37 μM and > 300 μM, respectively.

HY-107454

OSS_128167 30+ Cited Publications	Sirtuin HBV	Infection Metabolic Disease Inflammation/Immunology Cancer
OSS_128167 is a potent selective sirtuin 6 (SIRT6) inhibitor with IC₅₀s of 89 μM, 1578 μM and 751 μM for *SIRT6, SIRT1 and SIRT2, respectively. OSS_128167 has anti-HBV* activity that inhibits HBV transcription and replication. OSS_128167 has anti-cancer, anti-inflammation and anti-viral effects ^[2].

HY-100578

AGK2 15+ Cited Publications	Sirtuin Apoptosis	Cancer
AGK2 is a selective *SIRT2* inhibitor with an IC₅₀ of 3.5 μM. AGK2 inhibits *SIRT1* and *SIRT3* with IC₅₀s of 30 and 91 μM, respectively.

HY-15145A

SRT 1720 dihydrochloride 55+ Cited Publications	Sirtuin Autophagy	Metabolic Disease
SRT 1720 dihydrochloride is a selective and orally active activator of *SIRT1* with an EC₅₀ of 0.10 μM, and shows less potent activities on SIRT2 and SIRT3 .

HY-100591

SirReal2 2 Publications Verification	Sirtuin	Neurological Disease Inflammation/Immunology Cancer
SirReal2 is a potent, isotype-selective *Sirt2* inhibitor with an IC₅₀ value of 140 nM and has very little effect on the activities of Sirt3-5. SirReal2 leads to tubulin hyperacetylation in HeLa cells and induces destabilization of the checkpoint protein BubR1. SirReal2 combined with VS-5584 (HY-16585) suppresses tumor growth and extends the survival rate of mice in tumor xenograft model. SirReal2 is is promising for research of cancer, inflammation and neurodegeneration ^[2] .

HY-15510

Tenovin-6 5 Publications Verification	MDM-2/p53 Dihydroorotate Dehydrogenase Sirtuin Autophagy	Cancer
Tenovin-6, an analog of Tenovin-1 (HY-13423), is an activator of p53 transcriptional activity. Tenovin-6 inhibits the protein deacetylase activities of purified human SIRT1, SIRT2, and SIRT3 with IC₅₀s of 21 μM, 10 μM, and 67 μM, respectively. Tenovin-6 also inhibits dihydroorotate dehydrogenase (DHODH) ^[2].

HY-16691

AK-7 5+ Cited Publications	Sirtuin	Neurological Disease
AK-7 is a selective cell- and brain-permeable *SIRT2* inhibitor, with an IC₅₀ of 15.5 μM.

HY-B0150R

Nicotinamide (Standard) Maximum Cited Publications 89 Publications Verification Niacinamide(Standard); Nicotinic acid amide (Standard)	Reference Standards Endogenous Metabolite Sirtuin	Cancer
Nicotinamide (Standard) is the analytical standard of Nicotinamide. This product is intended for research and analytical applications. Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits *SIRT2* activity (IC₅₀: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD₊, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity ^[2] .

HY-103636

*PROTAC Sirt2* Degrader-1** 1 Publications Verification	Sirtuin PROTACs	Cancer
PROTAC Sirt2 Degrader-1 is a SirReal-based PROTAC, acts as a *Sirt2* degrader, composed of a highly potent and isotype-selective *Sirt2* inhibitor, a linker, and a bona fide Cereblon ligand for E3 ubiquitin ligase. PROTAC Sirt2 Degrader-1 shows an IC₅₀ of 0.25 μM for Sirt2, with no effect on Sirt1/Sirt3 (IC₅₀s>100 μM) .

HY-101278

Thiomyristoyl 5 Publications Verification	Sirtuin	Cancer
Thiomyristoyl is a potent and specific *SIRT2* inhibitor with an IC₅₀ of 28 nM.

HY-124037

SRT 1460 5+ Cited Publications	Sirtuin	Cancer
SRT 1460, a potent Sirtuin-1 (SIRT1) activator with an EC_1.5 value of 2.9 μM, shows good selectivity for activation of SIRT1 versus SIRT2 and SIRT3 (EC1.5>300 μM), and is more potent than Resveratrol and the closest sirtuin homologues .

HY-B0879

Suramin	Phosphatase Sirtuin Reverse Transcriptase Topoisomerase SARS-CoV Parasite Apoptosis	Infection Cardiovascular Disease Cancer
Suramin is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor . Suramin is a potent inhibitor of sirtuins: SirT1 (IC₅₀=297 nM), SirT2 (IC₅₀=1.15 μM), and SirT5 (IC₅₀=22 μM) ^[2]. Suramin is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC₅₀=5 μM) . Suramin is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor .Suramin efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent .

HY-101073

Salermide 3 Publications Verification	Sirtuin Apoptosis	Cancer
Salermide is an inhibitor of *Sirt1* and *Sirt2*; can cause strong cancer-specific apoptotic cell death.

HY-101465

AK-1	Sirtuin	Neurological Disease
AK-1 is a potent, specific and cell-permeable *SIRT2* inhibitor, with an IC₅₀ of 12.5 μM.

HY-112427

Sirt2-IN-1	Sirtuin	Inflammation/Immunology Cancer
Sirt2-IN-1 (Compound 9) is a sirtuin 2 (Sirt2) inhibitor with an IC₅₀ of 163 nM .

HY-100732

Cambinol 4 Publications Verification	Exosomes Sirtuin Apoptosis Phospholipase	Cancer
Cambinol is a *SIRT1* and *SIRT2* inhibitor with IC₅₀ values of 56 μM and 59 μM, respectively. Cambinol is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) ^[2].

HY-N1926

Dihydrocoumarin Hydrocoumarin; Chroman-2-one	Sirtuin	Cancer
Dihydrocoumarin is a compound found in Melilotus officinalis. Dihydrocoumarin is a yeast Sir2p inhibitor. Dihydrocoumarin also inhibits human SIRT1 and *SIRT2* with IC₅₀s of 208 μM and 295 μM, respectively .

HY-13423

Tenovin-1 5 Publications Verification	MDM-2/p53 Dihydroorotate Dehydrogenase Sirtuin Autophagy	Cancer
Tenovin-1, a p53 activator, protects p53 from MDM2-mediated degradation. Tenovin-1 acts through inhibition of the protein-deacetylating activities of SirT1 and SirT2. Tenovin-1 is also a dihydroorotate dehydrogenase (DHODH) inhibitor ^[2].

HY-148712

SIRT6 activator 12q	Apoptosis Sirtuin	Cancer
SIRT6 activator 12q is potent, selective and orally active *SIRT6* activator with IC₅₀ values of 171.20, >200, >200, >200, 0.58 μM for SIRT1, SIRT2, SIRT3, SIRT5, SIRT6, respectively. SIRT6 activator 12q inhibits cell growth and migration. SIRT6 activator 12q induces Apoptosis and cell cycle arrest at G2 phase. SIRT6 activator 12q shows anticancer activity .

HY-107660

SIRT2-IN-8	Sirtuin	Neurological Disease
SIRT2-IN-8 is a potent *SIRT2* inhibitor. SIRT2-IN-8 can be used for Huntington’s and Parkinson’s diseases research .

HY-15145

SRT 1720 monohydrochloride 55+ Cited Publications	Sirtuin Autophagy	Metabolic Disease
SRT 1720 monohydrochloride is a selective and orally active activator of *SIRT1* with an EC₅₀ of 0.10 μM, and shows less potent activities on SIRT2 and SIRT3 .

HY-15510B

Tenovin-6 Hydrochloride 5 Publications Verification	MDM-2/p53 Dihydroorotate Dehydrogenase Sirtuin Autophagy	Cancer
Tenovin-6 Hydrochloride, an analog of Tenovin-1 (HY-13423), is an activator of p53 transcriptional activity. Tenovin-6 Hydrochloride inhibits the protein deacetylase activities of purified human SIRT1, SIRT2, and SIRT3 with IC₅₀s of 21 μM, 10 μM, and 67 μM, respectively. Tenovin-6 Hydrochloride also inhibits dihydroorotate dehydrogenase (DHODH) ^[2].

HY-RS12940

SIRT2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
SIRT2 Human Pre-designed siRNA Set A contains three designed siRNAs for SIRT2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SIRT2 Human Pre-designed siRNA Set A SIRT2 Human Pre-designed siRNA Set A

HY-108986

JFD00244	Sirtuin SARS-CoV	Cancer
JFD00244 is a sirtuin 2 (SIRT2) inhibitor, with anti-tumor effect. JFD00244 is also a Nsp-16 inhibitor against *SARS-CoV-2* ^[2].

HY-123194

SIRT2/6-IN-1	Histone Demethylase Sirtuin	Metabolic Disease
SIRT2/6-IN-1 (Compound 5) is a *SIRT6/SIRT2* inhibitor, with IC₅₀s of 106 μM and 114 μM. SIRT2/6-IN-1 increases H3K9 acetylation, increases glucose uptake and reduces TNF-α secretion in cells .

HY-136199

SIRT1-IN-1 1 Publications Verification	Sirtuin CMV	Infection
SIRT1-IN-1 is a selective *SIRT1* inhibitor with an IC₅₀ of 0.205 μM. SIRT1-IN-1 inhibits SIRT2 with an IC₅₀ of 11.5 μM . SIRT1-IN-1, a indole, is a cytomegalovirus (CMV) inhibitors and has antiviral activity ^[2].

HY-118343

AC-93253	Sirtuin	Cancer
AC-93253 is a selective, potent *SIRT2* inhibitor. AC93253 can inhibit SIRT2 with an IC₅₀ value of 6 μM. AC93253 can be used for the research of tumors .

HY-111329

JGB1741 1 Publications Verification ILS-JGB-1741	Sirtuin Apoptosis	Cancer
JGB1741 (ILS-JGB-1741) is a potent and specific *SIRT1* activity inhibitor with an IC₅₀ of ∼15 μM. JGB1741 is a weak SIRT2 and SIRT3 inhibitor with an all IC₅₀>100 μM. JGB1741 increases the acetylated p53 levels leading to p53-mediated apoptosis with modulation of Bax/Bcl2 ratio, cytochrome c release and PARP cleavage. JGB1741 has the potential for breast cancer research .

HY-139144

YM-08	Sirtuin HSP	Neurological Disease Cancer
YM-08 (Compounds 7a) is a brain-penetrant inhibitors of *SIRT2*,with the IC₅₀ of 19.9 μM. YM-08 also is inhibitor of Hsp70 .

HY-133998

SIRT-IN-3 1 Publications Verification	Sirtuin	Cancer
SIRT-IN-3 is a potent *SIRT* inhibitor, with an IC₅₀ of 17 μM for SIRT1. SIRT-IN-3 shows about 4-fold and 14-fold selectivity for SIRT1 over SIRT2 and SIRT3, respectively (IC₅₀ of 74 μM and 235 μM for SIRT2 and SIRT3, respectively) .

HY-179388

*PROTAC Sirt2* Degrader-2**	PROTACs Sirtuin Apoptosis Akt mTOR	Cancer
PROTAC Sirt2 Degrader-2 is a highly efficient and selective PROTAC degrader targeting *SIRT2. PROTAC Sirt2* Degrader-2 demonstrates the most potent anti-proliferative activity both in vitro and in vivo. PROTAC Sirt2 Degrader-2 leads to a marked increase in H4K16Ac levels. PROTAC Sirt2 Degrader-2 significantly suppresses clonogenic formation and migration, induces cell cycle arrest, and promotes apoptosis. PROTAC Sirt2 Degrader-2 inhibits the AKT/mTOR signaling pathway by indirectly degrading SIRT2 and blocking downstream protein phosphorylation, thereby disrupting the signaling cascade and suppressing tumor development. PROTAC Sirt2 Degrader-2 can be used for the study of ovarian cancer .

HY-111522

RK-9123016	Sirtuin c-Myc	Cancer
RK-9123016 is a potent inhibitor of SIRT2. RK-9123016 inhibits the enzymatic activity of SIRT2 with an IC₅₀ value of 0.18 µM but not other human sirtuin members including SIRT1 and SIRT3 at 100 µM. RK-9123016 increases the acetylation level of eukaryotic translation initiation factor 5A (eIF5A), a physiological substrate of SIRT2, and reduces cell viability of human breast cancer cells accompanied with a decrease in c-Myc expression .

HY-178970

HDAC11-IN-4	HDAC	Cancer
HDAC11-IN-4 is a potent and selective HDAC11 inhibitor with an IC₅₀ of 13.49 nM and a K_i of 2.2 nM. HDAC11-IN-4 exhibits extremely high selectivity for HDAC11 over other defatty-acylases such as SIRT2, SIRT3, SIRT6, and HDAC8 (SI >10,000). HDAC11-IN-4 can be used for the research of cancer .

HY-112428

Sirt2-IN-2	Sirtuin	Inflammation/Immunology
Sirt2-IN-2 (Compound 10) is a selective *Sirt2* inhibitor with an IC₅₀ of 0.118 μM .

HY-148408

SIRT2-IN-11	Sirtuin	Cancer
SIRT2-IN-11 (AEM1) is a selective *SIRT2* inhibitor with an IC₅₀ value of 18.5 μM. SIRT2-IN-11 p53-dependently induces apoptosis, activates expression of CDKN1A, PUMA and NOXA, and increases acetylation of p53. SIRT2-IN-11 can be used for the research of p53-related cancers .

HY-W197205

SL010110	Sirtuin Histone Acetyltransferase PEPCK	Metabolic Disease
SL010110 is an anti-hyperglycemic agent. SL010110 potently inhibits gluconeogenesis by inhibiting *SIRT2, activating p300, and subsequently promoting PEPCK1* degradation. SL010110 downregulates the protein level of PEPCK1 without affecting the gene expressions of PEPCK, glucose-6-phosphatase, and fructose-1,6-bisphosphatase. SL010110 significantly improves glucose homeostasis in type 2 diabetic (T2D) mice model. SL010110 can be used for T2D research .

HY-178773

SIRT2-IN-18	Sirtuin Apoptosis	Infection
SIRT2-IN-18 (Compound 8) is a *SIRT2* inhibitor with IC₅₀s of 5.3  and 12.3 μM for SmSIRT2 and hSIRT2, respectively. SIRT2-IN-18 shows potent antischistosomal activities against both Liberian and Puerto Rican strains of Schistosoma mansoni and reduces schistosomula and adult worm pair viability, pairing, and egg production, with low cytotoxicity in mammalian cells. SIRT2-IN-18 increases histone H3 hyperacetylation and induces cytochrome c-mediated apoptosis .

HY-RS12942

Sirt2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Sirt2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sirt2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sirt2 Rat Pre-designed siRNA Set A Sirt2 Rat Pre-designed siRNA Set A

HY-RS12941

Sirt2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Sirt2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sirt2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sirt2 Mouse Pre-designed siRNA Set A Sirt2 Mouse Pre-designed siRNA Set A

HY-123653

SirReal-1	Sirtuin	Cancer
SirReal-1 is a potent and selective *Sirt2* inhibitor (IC50 = 3.7 μM) .

HY-145958

Sirt2-IN-6	Sirtuin	Cancer
Sirt2-IN-6 (compound 24a) potent and selective inhibitor of *SIRT2, with an IC₅₀* of 0.815 μM. Sirt2-IN-6 can be used for the research of cancer .

HY-149637

*HSP70/SIRT2-IN-1*	Sirtuin HSP	Cancer
HSP70/SIRT2-IN-1 (Compounds 2a) is a dual inhibitor for SIRT2 and HSP70, with IC₅₀ of 17.3±2.0 μM for SIRT2. HSP70/SIRT2-IN-1 has antitumor activity .

HY-149638

*HSP70/SIRT2-IN-2*	Sirtuin HSP	Cancer
HSP70/SIRT2-IN-2 (Compounds 1a) is a dual inhibitor for SIRT2 and HSP70, with IC₅₀ of 45.1±5.0 μM for SIRT2. HSP70/SIRT2-IN-2 has antitumor activity .

HY-119857

AGK7 SIRT2 Inhibitor,Inactive Control	Sirtuin	Neurological Disease
AGK7 is a potent inhibitor of sirtuin 2 (SIRT2). AGK7 rescues alpha-synuclein toxicity and modified inclusion morphology in a cellular model of Parkinson's disease. AGK7 protects against dopaminergic cell death both in vitro and in a Drosophila model of Parkinson's disease .

HY-B0150A

Nicotinamide hydrochloride Niacinamide hydrochloride; Nicotinic acid amide hydrochloride	Sirtuin Endogenous Metabolite HBV	Infection Cancer
Nicotinamide hydrochloride is a form of vitamin B3 or niacin. Nicotinamide hydrochloride inhibits *SIRT2* activity (IC₅₀: 2 μM). Nicotinamide hydrochloride also inhibits SIRT1. Nicotinamide hydrochloride increases cellular NAD₊, ATP, ROS levels. Nicotinamide hydrochloride inhibits tumor growth and improves survival. Nicotinamide hydrochloride also has anti-HBV activity ^[2] .

HY-10532R

SRT 1720 (Standard)	Reference Standards Sirtuin Autophagy	Metabolic Disease
SRT 1720 (Standard) is the analytical standard of SRT 1720. This product is intended for research and analytical applications. SRT 1720 is a selective activator of human SIRT1 with an EC1.5 of 0.16 μM, and shows less potent activities for SIRT2 and SIRT3 with EC1.5s of 37 μM and > 300 μM, respectively.

HY-155727

Sirt1/2-IN-2	Sirtuin Apoptosis	Cancer
Sirt1/2-IN-2 (compound hsa55) is a dual inhibitor of SIRT1/2 with IC₅₀s of 1.8 μM (SIRT1) and 2.4 μM (SIRT2), respsectivley. Sirt1/2-IN-2 completely blocks p53 deacetylation, and increase of p53 and α-tubulin acetylation. Sirt1/2-IN-2 induces apoptosis and shows anti-proliferation activity against human leukemia cell lines .

HY-147233

MIND4-19	Sirtuin	Neurological Disease
MIND4-19 is a potent *SIRT2* inhibitor with an IC₅₀ value of 7.0 μM. MIND4-19 can be used for researching Huntington's disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0150

Nicotinamide 85+ Cited Publications Niacinamide; Nicotinic acid amide	Alkaloids Structural Classification Human Gut Microbiota Metabolites Microorganisms Neurological Disease Classification of Application Fields Pyridine Alkaloids Endogenous metabolite Disease Research Fields Source Classification Cancer	Environmental Pollutants Endogenous Metabolite Sirtuin HBV Organoid
Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits *SIRT2* activity (IC₅₀: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD₊, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity ^[2] .

HY-N1926

Dihydrocoumarin Hydrocoumarin; Chroman-2-one	other families Classification of Application Fields Coumarins Phenylpropanoids Plants Disease Research Fields Source Classification Cancer	Sirtuin
Dihydrocoumarin is a compound found in Melilotus officinalis. Dihydrocoumarin is a yeast Sir2p inhibitor. Dihydrocoumarin also inhibits human SIRT1 and *SIRT2* with IC₅₀s of 208 μM and 295 μM, respectively .

HY-113355

NADH	Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	Endogenous Metabolite Apoptosis
NADH is an orally active dehydrogenase coenzyme that acts as a crucial electron carrier in cellular respiration and participates in ATP production. NADH promotes metabolism, supports brain function, and counteracts oxidative stress by transferring electrons to the electron transport chain. As a signaling molecule, NADH regulates multiple biological processes, including anti-apoptosis, synaptic plasticity, gene expression, and calcium homeostasis. Redox imbalance of NADH/NAD⁺ is one of the key pathological mechanisms of various diseases, such as diabetic nephropathy, neurodegenerative diseases, and ischemia-reperfusion injury.

HY-B0150A

Nicotinamide hydrochloride Niacinamide hydrochloride; Nicotinic acid amide hydrochloride	Infection Structural Classification Alkaloids Classification of Application Fields Pyridine Alkaloids Endogenous metabolite Disease Research Fields Source Classification Cancer	Sirtuin Endogenous Metabolite HBV
Nicotinamide hydrochloride is a form of vitamin B3 or niacin. Nicotinamide hydrochloride inhibits *SIRT2* activity (IC₅₀: 2 μM). Nicotinamide hydrochloride also inhibits SIRT1. Nicotinamide hydrochloride increases cellular NAD₊, ATP, ROS levels. Nicotinamide hydrochloride inhibits tumor growth and improves survival. Nicotinamide hydrochloride also has anti-HBV activity ^[2] .

HY-N9892

Guttiferone G	Garcinia xanthochymus Hook. f. ex T. Anders. Guttiferae Phenols Polyphenols Plants Source Classification	Sirtuin
Guttiferone G inhibits recombinant human *SIRT1* and *SIRT2* (IC₅₀: 9 and 22 μM, respectively). Guttiferone G is weakly cytotoxic in A2780 human ovarian cell line (IC₅₀: 8.0 μg/mL). Guttiferone G can be isolated from Garcinia macrophylla ^[2].

HY-N1926R

Dihydrocoumarin (Standard) Hydrocoumarin (Standard); Chroman-2-one (Standard)	Structural Classification other families Coumarins Phenylpropanoids Plants Source Classification	Reference Standards Sirtuin
Dihydrocoumarin (Standard) is the analytical standard of Dihydrocoumarin. This product is intended for research and analytical applications. Dihydrocoumarin is a compound found in Melilotus officinalis. Dihydrocoumarin is a yeast Sir2p inhibitor. Dihydrocoumarin also inhibits human SIRT1 and SIRT2 with IC50s of 208 μM and 295 μM, respectively .

Cat. No.	Product Name	Chemical Structure

HY-B0150S3

Nicotinamide-d3

Nicotinamide-d₃ (Niacinamide-d₃) is deuterium labeled Nicotinamide. Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC₅₀: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD₊, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity ^[2] .

HY-W744757

Nicotinamide-15N

Nicotinamide- ¹⁵N (Niacinamide- ¹⁵N) is the deuterium labeled Nicotinamide (HY-B0150). Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC₅₀: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD+, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity.

HY-15510S

Tenovin-6-d6
Tenovin-6-d₆ is the deuterium labeled Tenovin-6 (HY-15510). Tenovin-6, an analog of Tenovin-1 (HY-13423), is an activator of p53 transcriptional activity. Tenovin-6 inhibits the protein deacetylase activities of purified human SIRT1, SIRT2, and SIRT3 with IC₅₀s of 21 μM, 10 μM, and 67 μM, respectively. Tenovin-6 also inhibits dihydroorotate dehydrogenase (DHODH).

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0150G

Nicotinamide Niacinamide; Nicotinic acid amide	Endogenous Metabolite Sirtuin HBV	Infection Cancer
Nicotinamide (GMP) (Niacinamide (GMP)) is the GMP level of Nicotinamide (HY-B0150). GMP guidelines are used to produce Nicotinamide (GMP). GMP small molecules works appropriately as an auxiliary reagent for cell research manufacture. Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits *SIRT2* activity (IC₅₀: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD₊, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity ^[2] .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks